Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2015 / Feb / Cancer. Bad Habits or Bad Luck?
Research & Innovations

Cancer. Bad Habits or Bad Luck?

Sensational headlines like “Most cancer is bad luck” aren’t helpful– so what’s the real story?

By Mark Hillen 2/10/2015 1 min read

Share

A recent article in Science magazine (1) generated a raft of headlines shouting “Most cancer types ‘just bad luck’” with subheadings like “Most types of cancer can be put down to bad luck rather than risk factors such as smoking” (bit.ly/bbccancer). It seems that in some news outlets, the topline message being pitched was that modifiable risk factors like drinking, smoking and overeating aren’t really that important – now that cancer is mostly just bad luck. The importance of modifiable risk factors was mentioned later in the article – but at a point where most people have stopped reading (bit.ly/DMcancer;bit.ly/poynterinst). Not ideal.

So what did this “shock new study” (bit.ly/dailymirrorshock) actually find? The study’s authors wanted to understand why cancer risk varies between different tissues in the body – the average lifetime risk of lung cancer is around 1 in 14 (bit.ly/CRCUK), but for uveal melanoma, it’s closer to 1 in 13,000 (2). Their hypothesis: cancer risk is related to the number of stem cell divisions required to maintain a tissue. The adult eye undergo very few divisions; intestinal epithelia undergoes an awful lot. They examined the incidence of cancer occurrence across 31 tissue types, in order to gain an understanding of the relative contribution of unforced errors in cell division to cancer. What they found was pretty uncontroversial: greater proliferation rates increase the risk of developing cancer; and that ~65 percent of cancers were explained by this association – hence the headlines, although hardly good copy, and the fairly wide confidence intervals (95% CI; 39 to 85 percent) never made it into the newspapers… People can’t cheat chance, but the remaining 35 percent (or anywhere between the CI’s 15 to 61 percent range) can be influenced with those unpopular lifestyle interventions listed above. As PZ Myers put it: “If you were going off to the casino to shoot craps, you wouldn’t sneer at something that gave you a 10 percent edge on the table?” (bit.ly/pzmyers).

Of course “Study shows that a complex interaction of random molecular events, genetic propensity, environment and lifestyle” isn’t exactly a catchy headline. When it comes to healthcare stories, news outlets take a very “black and white” view: X is either the elixir of life, or out to kill you, as illustrated by the Daily Mail Oncological Ontology project (bit.ly/DMOOP). Perhaps a few shades of grey  (about 50 should do it) would restore a little reason to the debate.

About the Author(s)

Mark Hillen

I spent seven years as a medical writer, writing primary and review manuscripts, congress presentations and marketing materials for numerous – and mostly German – pharmaceutical companies. Prior to my adventures in medical communications, I was a Wellcome Trust PhD student at the University of Edinburgh.

More Articles by Mark Hillen

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: